Hi ralom, bye and bye I agree, for what it is worth. We only disagree on the ‘ ... if major change in management ..’ comment.
Nature of the beast, (believe WP also used this ‘telling quote’) is that this gig, like any other in the ‘fairy tale’ stage has a hard slog of realising its potential, especially in the bio health and Oiler sectors (own FAR shares!), however ‘good’ the story.
90% will fail!.
Much acclaim when WP come on board and then the ‘A’ team following, hard/impossible to NOT have approved at the time, I doubt if anyone at the time had a negative comment to make.
Perhaps only myself; said I would reserve judgement, later that if WP could not ‘pull it off’ no one else could have either (individual).
Lex did make a valid point, whether applicable to WP OR not, on a lot of occasions these folk coming from a major entity have run their course and move on to these types of gigs, big fish in a small pond.
It it does happen, if it was that easy to ‘turn around a company’ by employing said personal then every speccy would ‘headhunt’ these figures.
Easy to say ‘replace mangerment’, too easy ....... with who?
Admedus story may have been successful if in the hands of a major pharma, ideally, why?
Virtually unlimited funds to advance cause, established footprint to successfully commercialise and being a encumbered ‘giant’ a huge advantage in being competitive.
Alternative to that is a PE group.
Future; imo, sell off of infusion division a ‘bandaid’ to stem major bleeding, absolutely must be coupled up with major funds from other sources (TAVR most obvious).
Be interesting to see the quarterly figures if infusion sold off; effect on bottom line ( revenue) AND staff costs.
Meanwhile what the heck is the hold up on the MOU on the vaccine division?
There said only folk not worried about their investment, long term, is SB and SIO, retail investors, imo, have long since lost hope of making money, only hope now to minimise huge losses.
AHZ Price at posting:
3.6¢ Sentiment: None Disclosure: Held
(20min delay)